NCT03583281 (OXBIO) is a NA clinical trial of Capsules containing flax oil in Obesity, sponsored by University of Manitoba.

Who is sponsoring NCT03583281?

NCT03583281 is sponsored by University of Manitoba.

What drugs are being tested in NCT03583281?

Interventions in NCT03583281: Capsules containing flax oil, Capsules containing DHA-enriched fish oil.

What condition does NCT03583281 study?

NCT03583281 studies Obesity, Inflammation.

Is NCT03583281 still recruiting?

NCT03583281 is currently completed. Last updated 2 July 2021.

Last reviewed 2021-07-02 · How we verify

NCT03583281: OXBIO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Dietary Fatty Acids on Octadecanoid Production and Biological Actions in Obesity-induced Inflammation

Completed NA Last updated 2 July 2021

What this trial tests

NA trial testing Capsules containing flax oil in Obesity in 24 participants. Completed in 30 April 2021.

Timeline

1 June 2018

Primary endpoint
30 April 2020

30 April 2021

Quick facts

Lead sponsor	University of Manitoba
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	1 June 2018
Primary completion	30 April 2020
Estimated completion	30 April 2021
Sites	1 location across Canada

Drugs / interventions tested

Capsules containing flax oil
Capsules containing DHA-enriched fish oil

Conditions studied

Obesity — all drugs for Obesity →
Inflammation — all drugs for Inflammation →

Sponsor

University of Manitoba

Who can join

Adults 20 to 55, female only, with Obesity or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single site, double-blind, randomized, crossover study designed to compare the effects of dietary supplementation with flax oil rich in alpha-linolenic acid (ALA) and fish oil rich in docosahexaenoic acid (DHA) on oxylipin profiles over time (0 to 4 weeks) and among obese females varying in their inflammatory state. Additional assessments will include plasma fatty acid composition, adipokines, markers of adipocyte dysfunction and inflammation; immune cell/monocyte fatty acid composition, and functional properties including their metabolism and oxylipin production; and vascular function.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Oils Rich in α-Linolenic Acid or Docosahexaenoic Acid Have Distinct Effects on Plasma Oxylipin and Adiponectin Concentrations and on Monocyte Bioenergetics in Women with Obesity.
Pauls SD, Rodway LR, Sidhu KK, Winter T, et al · · 2021 · cited 21× · PMID 34293124 · DOI 10.1093/jn/nxab235
Distinct effects of α-linolenic acid and docosahexaenoic acid on the expression of genes related to cholesterol metabolism and the response to infection in THP-1 monocytes and immune cells of obese humans.
Rodway LA, Pauls SD, Pascoe CD, Aukema HM, et al · · 2023 · cited 9× · PMID 36621145 · DOI 10.1016/j.biopha.2022.114167
Long Chain N3-PUFA Decreases ACE2 Protein Levels and Prevents SARS-CoV-2 Cell Entry.
Huang S, Taylor CG, Zahradka P. · · 2022 · cited 4× · PMID 36430303 · DOI 10.3390/ijms232213825

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other University of Manitoba trials

Trials by the same sponsor.

NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03583281 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 2 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03583281.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing